EA201200181A1 - Защита клеток пациентов на диализе путём введения соединений креатина - Google Patents

Защита клеток пациентов на диализе путём введения соединений креатина

Info

Publication number
EA201200181A1
EA201200181A1 EA201200181A EA201200181A EA201200181A1 EA 201200181 A1 EA201200181 A1 EA 201200181A1 EA 201200181 A EA201200181 A EA 201200181A EA 201200181 A EA201200181 A EA 201200181A EA 201200181 A1 EA201200181 A1 EA 201200181A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protection
creatine compounds
dialysed
introducing
patient cells
Prior art date
Application number
EA201200181A
Other languages
English (en)
Other versions
EA022387B1 (ru
Inventor
Ульрих Киршнер
Original Assignee
Кририн Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кририн Лтд. filed Critical Кририн Лтд.
Publication of EA201200181A1 publication Critical patent/EA201200181A1/ru
Publication of EA022387B1 publication Critical patent/EA022387B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Abstract

Изобретение в основном относится к защите клеток у пациентов на гемодиализе путём введения диализных жидкостей, содержащих достаточное количество соединений креатина, и, в частности, к использованию соединений креатина для противодействия патофизиологическим состояниям, возникающим у пациентов на гемодиализе в ходе проведения общепринятых процедур гемодиализа или перитонеального диализа.
EA201200181A 2009-07-24 2010-07-21 Диализный раствор, содержащий соединение креатина, набор и твердый препарат для его приготовления EA022387B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09009618 2009-07-24
PCT/EP2010/004458 WO2011009601A1 (en) 2009-07-24 2010-07-21 Cell protection in dialysis patients by administration of a creatine compound

Publications (2)

Publication Number Publication Date
EA201200181A1 true EA201200181A1 (ru) 2012-06-29
EA022387B1 EA022387B1 (ru) 2015-12-30

Family

ID=41066061

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200181A EA022387B1 (ru) 2009-07-24 2010-07-21 Диализный раствор, содержащий соединение креатина, набор и твердый препарат для его приготовления

Country Status (14)

Country Link
US (1) US8791078B2 (ru)
EP (1) EP2456431B1 (ru)
JP (1) JP5847712B2 (ru)
CN (2) CN102573828B (ru)
AU (1) AU2010275752B2 (ru)
BR (1) BR112012001320B1 (ru)
CA (1) CA2769133C (ru)
EA (1) EA022387B1 (ru)
ES (1) ES2790948T3 (ru)
IL (1) IL217336A (ru)
IN (1) IN2012DN00399A (ru)
PL (1) PL2456431T3 (ru)
WO (1) WO2011009601A1 (ru)
ZA (1) ZA201200185B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736328B2 (en) 2007-07-05 2010-06-15 Baxter International Inc. Dialysis system having supply container autoconnection
EP2456431B1 (en) * 2009-07-24 2020-03-25 Crearene AG Dialysis solution comprising creatine for cell protection
CN102973599B (zh) * 2012-12-13 2014-04-23 天津金耀集团有限公司 腹膜透析液（乳酸盐）组合物
CA3022949A1 (en) 2016-05-06 2017-11-09 Gambro Lundia Ab Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation including testing thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US20030013767A1 (en) * 2001-07-13 2003-01-16 Samuel Bessman Method of treating weight loss using creatine
US20050276868A1 (en) * 2004-06-10 2005-12-15 Bart Degreve Bicarbonate-based peritoneal dialysis solutions
PL2416770T3 (pl) 2009-04-06 2017-06-30 Crearene Ltd. Roztwory do hemodializy i dializy otrzewnowej zawierające jeden lub więcej związków kreatyny
EP2456431B1 (en) * 2009-07-24 2020-03-25 Crearene AG Dialysis solution comprising creatine for cell protection

Also Published As

Publication number Publication date
IL217336A0 (en) 2012-02-29
US20120135943A1 (en) 2012-05-31
CN104382891B (zh) 2017-04-12
JP5847712B2 (ja) 2016-01-27
IN2012DN00399A (ru) 2015-08-21
CN102573828A (zh) 2012-07-11
CN104382891A (zh) 2015-03-04
CA2769133C (en) 2017-08-29
EA022387B1 (ru) 2015-12-30
AU2010275752B2 (en) 2016-09-01
PL2456431T3 (pl) 2020-08-24
BR112012001320B1 (pt) 2021-10-05
CA2769133A1 (en) 2011-01-27
EP2456431B1 (en) 2020-03-25
ZA201200185B (en) 2012-09-26
EP2456431A1 (en) 2012-05-30
US8791078B2 (en) 2014-07-29
BR112012001320A2 (pt) 2020-11-03
CN102573828B (zh) 2018-02-23
AU2010275752A1 (en) 2012-02-02
ES2790948T3 (es) 2020-10-30
IL217336A (en) 2016-09-29
WO2011009601A1 (en) 2011-01-27
JP2013500243A (ja) 2013-01-07

Similar Documents

Publication Publication Date Title
EA201290144A1 (ru) Многокамерный резервуар
BR112013026319A2 (pt) método e aparelho para o monitoramento de um tratamento de um paciente, preferivelmente para o monitoramento da hemodiálise, hemodiafiltração e/ou diálise peritoneal
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201201284A1 (ru) Система для обработки крови
NZ710157A (en) Use of guanethidine for treating hypertension by local vascular delivery
IL215504A0 (en) Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2012115772A3 (en) Therapy for kidney disease and/or heart failure
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2010001421A (es) Dializado peritoneal.
EA201500019A1 (ru) Способ лечения gd2-положительного рака
MX2016003788A (es) Sistema de sensor para la deteccion de fases y/o transicion de fase en los tratamientos de dialisis peritoneal.
EA201400994A1 (ru) Инфузионный адаптер для изменения давления внутри инфузионной магистрали в процессе лечения
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
EA201200181A1 (ru) Защита клеток пациентов на диализе путём введения соединений креатина
WO2012092305A3 (en) Nanonized iron compositions and methods of use thereof
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ

PC4A Registration of transfer of a eurasian patent by assignment